https://hepquant.com/posters-presentations/poster-of-distinction-the-oral-cholate-challenge-test-defines-likelihood-of-large-esophageal-varices-in-an-overweight-and-obese-us-population/ 2025-05-21T17:39:56+00:00 https://hepquant.com/posters-presentations/maintenance-therapy-with-glp-1-receptor-agonists-does-not-impact-the-clearance-of-orally-administered-isotopes-of-unconjugated-cholate/ 2025-05-21T18:16:35+00:00 https://hepquant.com/posters-presentations/cost-effectiveness-of-the-hepquant-duo-test-for-the-management-of-patients-at-risk-for-large-esophageal-varices/ 2025-05-21T18:18:54+00:00 https://hepquant.com/posters-presentations/poster-of-distinction-pilot-study-of-a-model-based-on-noninvasive-assessments-of-portal-systemic-shunting-hepquant-duo/ 2025-05-21T18:19:48+00:00 https://hepquant.com/posters-presentations/poster-of-distinction-resmetirom-therapy-of-mash-associated-child-pugh-a-cirrhosis-reduces-estimated-risk-for-clinical-outcome-based-on-hepquant-risk-ace-model/ 2025-05-21T18:20:47+00:00 https://hepquant.com/posters-presentations/the-oral-cholate-challenge-test-identifies-the-mash-patients-with-%e2%89%a5f3-fibrosis-with-greatest-hepatic-impairment-who-show-the-most-benefit-from-short-term-rencofilstat-therapy/ 2025-05-21T18:21:33+00:00 https://hepquant.com/posters-presentations/statins-and-metformin-may-preserve-hepatic-function-and-reduce-portal-systemic-shunting-in-advanced-chronic-liver-disease-results-with-the-hepquant-duo-test-from-the-shunt-v-study/ 2025-05-21T18:27:36+00:00 https://hepquant.com/posters-presentations/quantifying-the-individual-impact-of-cardiac-and-liver-disease-on-liver-function-and-portal-systemic-shunting-in-fontan-associated-liver-disease-by-a-simplified-cholate-shunt-test/ 2025-05-21T18:29:32+00:00 https://hepquant.com/posters-presentations/initial-clinical-experience-with-the-hepquant-duo-test-results-from-the-2023-2024-early-access-program/ 2025-05-21T18:31:33+00:00 https://hepquant.com/posters-presentations/the-oral-cholate-challenge-test-defines-likelihood-of-large-esophageal-varices-in-an-overweight-and-obese-u-s-population/ 2025-05-27T22:23:38+00:00 https://hepquant.com/posters-presentations/independent-analysis-of-early-clinical-practice-experience-with-the-hepquant-duo-test/ 2025-05-27T22:24:01+00:00 https://hepquant.com/posters-presentations/the-hepquant-duo-test-finds-linkage-between-liver-blood-flow-portal-systemic-shunting-and-cardiac-hemodynamics-in-fontan-associated-liver-disease/ 2025-05-27T22:26:26+00:00 https://hepquant.com/posters-presentations/hepquant-duo-for-quantifying-liver-function-and-physiology-in-the-clinic-diagnostic-performance-for-esophageal-varices-in-patients-with-treated-and-active-chronic-hepatitis-c/ 2025-05-27T22:29:19+00:00 https://hepquant.com/posters-presentations/quantifying-liver-function-by-cholate-clearance-in-extracorporeal-circuits-with-a-genetically-modified-porcine-liver-and-brain-dead-human-decedent/ 2025-05-27T22:30:52+00:00 https://hepquant.com/posters-presentations/pilot-study-of-a-model-based-on-noninvasive-assessments-of-portal-systemic-shunting-hepquant-duo-hepatic-fibrosis-fibroscan-and-splenic-congestion-platelet-count-for-accurate-prediction-of-por/ 2025-05-27T22:33:43+00:00 https://hepquant.com/posters-presentations/resmetirom-therapy-of-mash-associated-child-pugh-a-cirrhosis-reduces-estimated-risk-for-clinical-outcome-based-on-hepquant-risk-ace-model/ 2025-05-27T22:35:54+00:00 https://hepquant.com/posters-presentations/simultaneous-quantification-of-function-of-native-human-liver-and-porcine-liver-in-an-extracorporeal-circuit-derived-from-the-blood-concentrations-of-intravenously-injected-13c-cholate/ 2025-09-30T15:55:46+00:00 https://hepquant.com/posters-presentations/the-quantitative-hepquant-duo-test-uncovers-the-functional-heterogeneity-of-advanced-chronic-liver-disease/ 2025-09-30T16:03:55+00:00 https://hepquant.com/posters-presentations/resmetirom-therapy-of-mash-associated-child-pugh-a-cirrhosis-reduces-estimated-risk-for-clinical-outcome-based-on-hepquant-risk-ace-model-2/ 2026-03-11T19:46:36+00:00 https://hepquant.com/posters-presentations/the-oral-cholate-challenge-test-better-defines-disease-severity-in-advance-chronic-liver-disease-by-quantifying-liver-function-and-portal-systemic-shunting/ 2026-03-11T19:47:28+00:00 https://hepquant.com/posters-presentations/the-oral-cholate-challenge-test-better-defines-disease-severity-in-advanced-chronic-liver-disease-by-quantifying-liver-function-and-portal-systemic-shunting/ 2026-03-11T19:50:24+00:00 https://hepquant.com/posters-presentations/resmetirom-therapy-of-mash-associated-child-pugh-a-cirrhosis-reduces-estimated-risk-for-clinical-outcome/ 2026-03-11T19:51:20+00:00 https://hepquant.com/posters-presentations/the-oral-cholate-challenge-test-defines-likelihood-of-large-esophageal-varices-in-an-overweight-and-obese-u-s-population-2/ 2026-03-11T19:52:07+00:00 https://hepquant.com/posters-presentations/statins-and-metformin-preserve-hepatic-function-and-reduce-portal-systemic-shunting-in-advanced-chronic-liver-disease/ 2026-03-11T19:52:58+00:00 https://hepquant.com/posters-presentations/the-quantitative-hepquant-duo-test-uncovers-the-functional-heterogeneity-of-advanced-chronic-liver-disease-2/ 2026-03-11T19:55:34+00:00 https://hepquant.com/posters-presentations/understanding-the-functional-and-physiologic-heterogeneity-of-advanced-mash-as-defined-by-the-oral-cholate-challenge-test-may-enhance-clinical-trial-design/ 2026-03-11T19:56:45+00:00 https://hepquant.com/posters-presentations/dual-cholate-shunt-test-identifies-patients-at-risk-for-portal-hypertension-and-worsening-hemodynamics-in-two-cohorts-with-fontan-associated-liver-disease/ 2026-03-11T20:00:11+00:00 https://hepquant.com/posters-presentations/hepatic-reserve-and-regeneration-in-living-donors-after-right-hepatic-lobectomy-a-pilot-study-of-the-oral-cholate-challenge-test/ 2026-03-11T20:05:16+00:00 https://hepquant.com/posters-presentations/the-quantitative-hepquant-duo-test-uncovers-the-functional-heterogeneity-of-advanced-chronic-liver-disease-3/ 2026-03-11T20:09:52+00:00 https://hepquant.com/posters-presentations/a-patient-centric-model-for-measuring-risk-for-adverse-clinical-events-risk-ace-by-hepquant-duo/ 2026-03-11T20:11:08+00:00 https://hepquant.com/posters-presentations/noninvasive-quantification-of-portal-systemic-shunting-a-new-approach-to-assessment-of-the-portal-hypertension-and-the-portal-circulation/ 2026-03-27T15:00:30+00:00 https://hepquant.com/posters-presentations/noninvasive-quantification-of-liver-function-and-portal-systemic-shunting-distinguishes-differences-between-child-pugh-a5-and-a6-cirrhosis/ 2026-03-27T15:00:40+00:00 https://hepquant.com/posters-presentations/oral-cholate-challenge-test-stratifies-hepatotoxicity-risk-after-liver-directed-therapy-for-hepatocellular-carcinoma/ 2026-05-28T22:16:17+00:00 https://hepquant.com/posters-presentations/optimizing-drug-development-in-populations-with-compensated-mash-cirrhosis-by-integration-of-the-disease-severity-index-from-the-hepquant-duo-test-in-trial-design/ 2026-05-28T22:17:19+00:00 https://hepquant.com/posters-presentations/the-oral-cholate-challenge-test-detects-early-hepatic-improvement-with-ledipasvir-sofosbuvir-in-liver-transplant-recipients-and-patients-with-advanced-cirrhosis/ 2026-05-28T22:18:19+00:00